World Ophthalmology Congress 2010 Review

Article

At WOC 2010 there were 738 sessions and 1120 posters and over 13,000 people attended the Congress. OTEurope brings you a selection of Berlin highlights.

New era in the treatment of retinal vascular disease

"This will revolutionize our therapeutic approaches to the challenge of preventing avoidable blindness," declared Dr Lang. "The two most common retinal vascular diseases are diabetic retinopathy and retinal vein occlusions. Diabetic retinopathy is the leading cause of blindness in the working-age population. An estimated eight million people in Germany and 24 million in the United States suffer from diabetes mellitus. After individual patients have suffered from this problem for 15 years nearly 90 per cent of them with Type 1 and 84 per cent of them with Type 2 develop diabetic retinopathy. The relative risk of people in Germany going blind amounts to 5.2 per cent of the population.

"We have now experienced a major breakthrough in treatment of macular oedema related to diabetic retinopathy and vein occlusions. The RESOLVE and RESTORE studies from the Novartis company and the study of the DRCnet Group on treatment of DME with ranibizumab and they showed that ranibizumab is significantly more effective than the care offered by laser treatment. Similar to the breakthrough in AMD several years ago when we were able to improve vision in patients with wet AMD we now have reached the point that if we treat diabetic patients with ranibizumab they experience a significant improvement in visual acuity. In former days we were thinking about prevention of visual loss but now a new era starts and we can bring back vision to diabetic patients which is so important because diabetes is the most common cause of blindness in working-age people so the patients who could no longer work or drive can now, with the new VEGF treatment, work again and enjoy life.

"The second most common disease of the retina vessels is vein occlusion. It is and age-related disease. Beyond the age of 80, 4.6 per cent of the population is affected. The CRUISE and BRVO studies tested ranibizumab on vein occlusion with patients being given injections of the antibody or placebo over a six month period. In the BRVO study there was a noteable improvement in visual acuity. After six months, those patients who received a dosage of 0.5 mg of ranibizumab were able to read 18.3 letters or 3.7 lines more on the vision chart than the average. Those patients who received placebo injections gained seven letters or 1.4 lines on average.

"We have waited for forty years for this kind of breakthrough. We have worked in this area for a long time and tried several different compounds but have always been disappointed after around 6-8 years of work when we found they were not effective. This is the beginning of a new era."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.